Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S125-S143
Closed Access | Times Cited: 337

Showing 51-75 of 337 citing articles:

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
Young Sang Lyu, Seok Kyu Oh, Jin Hwa Kim, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
Leonardo de Andrade Mesquita, Laura Fink Wayerbacher, Gilberto Schwartsmann, et al.
Archives of Endocrinology and Metabolism (2023) Vol. 67, Iss. 6
Open Access | Times Cited: 17
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Antidiabetic Drugs in Breast Cancer Patients
Wojciech Garczorz, Agnieszka Kosowska, Tomasz Francuz
Cancers (2024) Vol. 16, Iss. 2, pp. 299-299
Open Access | Times Cited: 6
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung‐Il Park, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 2, pp. 312-320
Open Access | Times Cited: 6
Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes
Wei‐Han Chen, Yujia Li, Lanting Yang, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0297208-e0297208
Open Access | Times Cited: 6
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Jennifer B. Green, Brendan M. Everett, Alokananda Ghosh, et al.
Circulation (2024) Vol. 149, Iss. 13, pp. 993-1003
Closed Access | Times Cited: 6
Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Dan Xu, Ankith Nair, Charlie Sigston, et al.
Cardiovascular Therapeutics (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 28
Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
Ilaria Barchetta, Flavia Agata Cimini, Sara Dule, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2306-2306
Open Access | Times Cited: 27
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Kamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1187-1196
Open Access | Times Cited: 26
The Role of Beta Cell Recovery in Type 2 Diabetes Remission
Mara Suleiman, Lorella Marselli, Miriam Cnop, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7435-7435
Open Access | Times Cited: 26
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment
Vanita R. Aroda, Robert H. Eckel
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 12, pp. 2297-2308
Open Access | Times Cited: 26
Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0·9 million adults with Diabetes in Hong Kong (2002–2019)
Aimin Yang, Hongjiang Wu, Eric S. H. Lau, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 26, pp. 100509-100509
Open Access | Times Cited: 25
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2237606-e2237606
Open Access | Times Cited: 24
Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
Cesare Berra, Maria Chiara Rossi, Marco Mirani, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 16
Machine Learning Approach to Drug Treatment Strategy for Diabetes Care
Kazuya Fujihara, Hirohito Sone
Diabetes & Metabolism Journal (2023) Vol. 47, Iss. 3, pp. 325-332
Open Access | Times Cited: 15
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials
Pei-Chien Tsai, Wei-Jung Chuang, Albert Min‐Shan Ko, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 15
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Dóra Balogh, László Wagner, Andrea Fekete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7789-7789
Open Access | Times Cited: 15
Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Shiwen Yang, Ying Liu, Shengzhao Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Five-year Weight Loss Maintenance With Obesity Pharmacotherapy
Michael A. Weintraub, Debra D’Angelo, Beverly G. Tchang, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 9, pp. e832-e841
Open Access | Times Cited: 14
Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study
Huilin Tang, Jingchuan Guo, C. Elizabeth Shaaban, et al.
Alzheimer s & Dementia (2023) Vol. 20, Iss. 2, pp. 975-985
Open Access | Times Cited: 14
Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
Shimeng Liu, Jing Liu, Lei Si, et al.
BMJ Global Health (2023) Vol. 8, Iss. 4, pp. e010942-e010942
Open Access | Times Cited: 13
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Do Kyeong Song, Young Sun Hong, Yeon‐Ah Sung, et al.
PLoS ONE (2024) Vol. 19, Iss. 2, pp. e0299035-e0299035
Open Access | Times Cited: 5
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
Juan P. Frías, JaeDuk Choi, Julio Rosenstock, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1592-1600
Open Access | Times Cited: 22
Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study
Devin Abrahami, Helen Tesfaye, Hui Yin, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2907-2917
Open Access | Times Cited: 22

Scroll to top